Welcome back to another episode of Frankly Speaking!
On today’s show, I open up by breaking down the small-cap biotech sector. Jeff provides listeners with a perfect example of a biotech stock fighting for FDA approval.
I’ve seen this happen too many times…
From the pre-clinical stages… all the way through the approval process… these companies undertake extreme volatility. Step-by-step, I explain the lengthy process every small-cap biotech company must endure. In addition, I tell listeners exactly when it’s the best time to place their bets on these types of investments.
Then, after revisiting my position on Northern Dynasty (NAK), I dive into a very important lesson… Stop-loss orders. This is an investment tool every investor must use in order to prevent large portfolio deficits.
I often warn investors to not “show their hand”… Tune in to hear what I mean.
Finally, to end the episode, I dive into another sector that has just about topped-out. With interest rates going higher, I tell listeners why I’m avoiding this market going forward.
Special thanks to Brain, Jeff, Kenny, Craig, and Steve for all the great questions… Keep them coming!
Thanks for listening,